The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
about
A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies.New Therapeutic Agent against Arterial Thrombosis: An Iridium(III)-Derived Organometallic Compound.Norcantharidin, a clinical used chemotherapeutic agent, acts as a powerful inhibitor by interfering with fibrinogen-integrin αIIb β3 binding in human platelets.Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation.Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation.
P2860
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
@en
type
label
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
@en
prefLabel
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
@en
P2093
P2860
P1476
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
@en
P2093
Chih-Hao Yang
Joen-Rong Sheu
Pitchairaj Geraldine
Thanasekaran Jayakumar
Ting-Lin Yen
P2860
P304
P356
10.1080/17425255.2016.1176141
P407
P577
2016-04-07T00:00:00Z